MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

About this update from Mink Therapeutics, Inc.

NEW YORK , Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the Company will release its second quarter 2024 financial results before the market opens on August 13, 2024. MiNK executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and to provide a corporate update. Conference Call Dial-in numbers: 646-307-1963 ( New York ), 800-715-9871 ( USA & Canada ) Conference ID: 4021545 Webcast A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations and via https://edge.media-server.com/mmc/p/gwzqgg8t/ . About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY . For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Investor Contact 917-362-1370 [email protected] Media Contact 781-674-4428 [email protected] Source: MiNK Therapeutics

View stock analysis, news, and events for Mink Therapeutics, Inc.